Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
DiaMedica Therapeutics Inc.
Report date July 23, 2025 · Filed July 25, 2025
Section 16 reporting ended · disclosed 2025-07-25. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Voting Common Shares, no par value per shareSEC Table I · non-derivative | IndirectBy Roth IRA | 4,958,823 |
Reported balance
After 2025-07-23 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2025-07-23 · Purchase · Acquired 400,000 · Balance 4,958,823 F1: These shares are held by NFS/FMTC Roth IRA FBO Richard Jacinto II, of which Richard Jacinto II is the beneficiary. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares are held by NFS/FMTC Roth IRA FBO Richard Jacinto II, of which Richard Jacinto II is the beneficiary.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 23, 2025 Filed Jul 25, 2025 20:35 UTC | DiaMedica Therapeutics Inc. DMAC · Entity 5813 | PurchaseVoting Common Shares, no par value per share | 400,000 | $3.50 | $1,400,000.00 |
DisclosureSEC source: 0001437749-25-023532 · rdgdoc.xml · nonDerivative · entry 1 JACINTO RICHARD II · CIK 0001196834 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Roth IRA Disclosed balance after: 4,958,823 F1 · ownership.nature: These shares are held by NFS/FMTC Roth IRA FBO Richard Jacinto II, of which Richard Jacinto II is the beneficiary. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.